NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01761461,Phase III Randomized Trial of Adjuvant Chemotherapy With S-1 vs S-1/Oxaliplatin Â± Radiotherapy for Completely Resected Gastric Adenocarcinoma : The ARTIST II Trial,https://clinicaltrials.gov/study/NCT01761461,ARTIST-II,UNKNOWN,"The optimal regimen for adjuvant treatment has not been established in GC yet. We plan to compare TS-1, TS-1/oxaliplatin with or without RT in D2 resected gastric cancer.",NO,Gastric Cancer,"DRUG: TS-1, oxaliplatin","The primary endpoint of the study is disease-free survival (DFS)., 3-year",,,Samsung Medical Center,,ALL,"ADULT, OLDER_ADULT",PHASE3,547,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2012-06-061,2013-02-06,2020-12,2020-12,2013-01-04,,2020-03-25,"Samsung Medical Center, Seoul, Korea, Republic of",
